2026-04-13T00:01:11Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/124372025-10-24T10:25:50Zcom_2072_378070com_2072_378040col_2072_378092

00925njm 22002777a 4500 dc Chacon Garcia, Fernando author Morano Amado, Luis Enrique author Granados, José Rafael author Llibre, Josep M author Ryan, Pablo author Navarro, Jordi author 2025-01-20T09:39:02Z 2025-01-20T09:39:02Z 2024-11-14 Direct-acting antivirals; Hepatitis C; Reinfection Antivirales de acción directa; Hepatitis C; Reinfección Antivirals d'acció directa; Hepatitis C; Reinfecció Background Hepatitis C virus (HCV) reinfection following successful treatment threatens the achievement of HCV elimination. The primary aim of this study is to assess reinfection rate three years after sustained virologic response (SVR) in people who inject drugs (PWID) that are on opioid agonist treatment (OAT) who underwent anti-HCV treatment with interferon-free regimens. Methods Observational, non-interventional, prospective, descriptive study carried out in Spanish tertiary public hospitals between 2017 and 2022. Participants comprised 186 adult HCV infected individuals, 85.5% males with a mean age (Standard Deviation, SD) of 50.1 (5.9). All were enrolled in an OAT program at baseline and had attained SVR 12 weeks after therapy completion with an interferon-free treatment. Baseline data were abstracted from medical chart information collected through the routine clinical practice. Results The overall rate of HCV reinfection three years after SVR12 among PWID was 1.2 new cases per 100 person-years of follow-up at a median of 15.9 months. In the subgroup analyses, those with injection drug practice and without a stable housing had higher reinfection rates. Conclusion Although PWID in OAT present a low rate of reinfection by HCV after successful treatment, a closer monitoring in the first year and strengthening inter-consultations with services responsible for monitoring addiction in these patients will be crucial to reduce risky behaviors avoiding HCV reinfection. This study was sponsored and funded by MSD (Merck Sharp & Dohme Spain). http://hdl.handle.net/11351/12437 Medicaments antivírics - Ús terapèutic Abús de substàncies Hepatitis C - Tractament Hepatitis C - Recaiguda DISEASES::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Recurrence DISEASES::Virus Diseases::Hepatitis, Viral, Human::Hepatitis C Other subheadings::Other subheadings::Other subheadings::/drug therapy CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents DISEASES::Chemically-Induced Disorders::Substance-Related Disorders::Substance Abuse, Intravenous ENFERMEDADES::afecciones patológicas, signos y síntomas::procesos patológicos::atributos de la enfermedad::recurrencia ENFERMEDADES::virosis::hepatitis viral humana::hepatitis C Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antivíricos ENFERMEDADES::trastornos inducidos químicamente::trastornos relacionados con sustancias::abuso de sustancias por vía intravenosa Rate of hepatitis C reinfection after successful direct-acting antivirals treatment among people who inject drugs in Spain: the LIVERate study